A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis. Gras A, Broughton J Expert Rev Pharmacoecon Outcomes Res. 2016 Jan 9. PMID: 26750641. Abstract CommentRecommendBookmarkWatch